MARKET

HTBX

HTBX

Heat Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5170
+0.0820
+18.85%
Opening 14:13 11/19 EST
OPEN
0.4600
PREV CLOSE
0.4350
HIGH
0.5800
LOW
0.4400
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
2.100
52 WEEK LOW
0.3500
MARKET CAP
17.65M
P/E (TTM)
-0.7864
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of HTBX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

HTBX News

  • The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
  • Benzinga.6h ago
  • The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
  • Benzinga.6h ago
  • Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference
  • ACCESSWIRE.1d ago
  • Heat Biologics EPS misses by $0.05
  • seekingalpha.4d ago

More

Industry

Biotechnology & Medical Research
+2.04%
Pharmaceuticals & Medical Research
+0.68%

Hot Stocks

Name
Price
%Change

About HTBX

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
More

Webull offers Heat Biologics Inc (HTBX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.